Thailand Compulsory-Licensing Plan To Proceed Despite New Government
This article was originally published in PharmAsia News
Executive Summary
Although Thailand's military-appointed government is to be replaced soon by an elected government, plans to impose compulsory licensing on four cancer drugs are to proceed as planned. Public Health Minister Mongkol Na Songkhla said the decision was made on Jan. 4 and the pros and cons of the action had been thoroughly considered. Believed targeted for facing generic versions are letrozole and imatinib by Novartis, docetaxel by Sanofi-Aventis and erlotinib by Roche Holding. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.